Obstructive sleep apnea is ralated to metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus

阻塞性睡眠呼吸暂停与2型糖尿病相关的代谢功能障碍和脂肪肝疾病有关

阅读:1

Abstract

Obstructive sleep apnea (OSA) may be associated with the pathogenesis and severity of metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to determine the relationship between OSA and MASLD in type 2 diabetes mellitus (T2DM) patients. OSA was diagnosed via polysomnography, and liver ultrasound was used to measure the severity of MASLD in hospitalized patients with T2DM. The severity of OSA was categorized as non, mild, moderate, and severe according to the apnea-hypopnea index (AHI). Moreover, the oxygen desaturation index (ODI) and the lowest oxygen saturation (LSaO2) during sleep were recorded. Classification and analysis were conducted according to the level and severity of ODI and LSaO2. Age, sex, duration of diabetes, and history of smoking and drinking were recorded. Height and weight were measured, and BMI was calculated. Plasma glucose and serum lipid levels were assessed. Among the participants, 64.4% had both MASLD and OSA, 47.5% had moderate-to-severe MASLD, and 43.4% had moderate-to-severe OSA. In addition, 100% of severe MASLD patients had OSA, with 50% demonstrating moderate (8.3%) or severe (41.7%) OSA. A total of 91.5% of moderate-to-severe OSA patients had moderate-to-severe MASLD. A total of 62.5%, 58.5%, and 57.2% of moderate or severe MASLD patients had moderate or severe AHI, LSaO2, and ODI, respectively. AHI, LSaO2, and ODI were more serious in patients with moderate-to-severe MASLD than in those with non-to-mild MASLD. OSA was closely associated with the occurrence of moderate-to-severe MASLD after adjusting for age, sex, duration of diabetes, BMI, and blood lipid and blood glucose levels. In T2DM patients, the prevalence of OSA and MASLD is high, and the prevalence of MASLD is greater in moderate-to-severe OSA patients. The severity of MASLD was positively correlated with AHI, LSaO2, and ODI findings. OSA may aggravate the severity of MASLD, excluding other influencing factors, and vice versa, those with MASLD for OSA. Clinicians should screen OSA patients for the presence and severity of MASLD and vice versa.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。